PL4041748T3 - Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1 - Google Patents

Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1

Info

Publication number
PL4041748T3
PL4041748T3 PL20780745.4T PL20780745T PL4041748T3 PL 4041748 T3 PL4041748 T3 PL 4041748T3 PL 20780745 T PL20780745 T PL 20780745T PL 4041748 T3 PL4041748 T3 PL 4041748T3
Authority
PL
Poland
Prior art keywords
agonists
side effects
peptide compounds
reducing side
reducing
Prior art date
Application number
PL20780745.4T
Other languages
English (en)
Inventor
Vicent CASADÓ BURILLO
Estefania MORENO GUILLÉN
Rafael MALDONADO LÓPEZ
David ANDREU MARTÍNEZ
María GALLO
Leonardo PARDO CARRASCO
Miguel CASTANHO
Vera NEVES
Marco CAVACO
Original Assignee
Universitat De Barcelona
Universitat Pompeu Fabra
Universitat Autònoma De Barcelona
Instituto de Medicina Molecular João Lobo Antunes
Faculdade de medicina da universidade de Lisboa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Barcelona, Universitat Pompeu Fabra, Universitat Autònoma De Barcelona, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de medicina da universidade de Lisboa filed Critical Universitat De Barcelona
Publication of PL4041748T3 publication Critical patent/PL4041748T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20780745.4T 2019-10-03 2020-10-02 Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1 PL4041748T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382856.3A EP3800195A1 (en) 2019-10-03 2019-10-03 Peptide compounds for reducing side effects of cb1 receptor agonists
PCT/EP2020/077642 WO2021064165A1 (en) 2019-10-03 2020-10-02 Peptide compounds for reducing side effects of cb1 receptor agonists

Publications (1)

Publication Number Publication Date
PL4041748T3 true PL4041748T3 (pl) 2024-10-21

Family

ID=68281384

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20780745.4T PL4041748T3 (pl) 2019-10-03 2020-10-02 Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1

Country Status (9)

Country Link
US (1) US12459973B2 (pl)
EP (2) EP3800195A1 (pl)
JP (1) JP7781422B2 (pl)
CN (1) CN114641486B (pl)
AU (1) AU2020360716B2 (pl)
CA (1) CA3156280A1 (pl)
ES (1) ES2984754T3 (pl)
PL (1) PL4041748T3 (pl)
WO (1) WO2021064165A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252686A1 (en) 2024-06-03 2025-12-11 Universitat Pompeu Fabra Compounds for the treatment of cannabis use disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
DK2878306T3 (en) * 2012-07-13 2019-03-04 Proteimax Biotecnologia Ltda MODIFIED PEPTIDE, CB RECEPTOR LIGAND, KIT, IN VITRO PROCEDURE FOR EVALUATION OF CB RECEPTOR BINDINGS, APPLICATIONS, PHARMACEUTICAL COMPOSITION FOR MODULATING CBRECEPTOR ACTIVITY
US9656981B2 (en) * 2012-07-20 2017-05-23 The Regents Of The University Of California Peripherally-acting cannabinoid receptor agonists for chronic pain
US10654917B2 (en) 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders

Also Published As

Publication number Publication date
ES2984754T3 (es) 2024-10-30
EP4041748A1 (en) 2022-08-17
WO2021064165A1 (en) 2021-04-08
EP3800195A1 (en) 2021-04-07
JP7781422B2 (ja) 2025-12-08
AU2020360716A1 (en) 2022-04-21
EP4041748C0 (en) 2024-05-01
CA3156280A1 (en) 2021-04-08
JP2023504765A (ja) 2023-02-07
US20240059737A1 (en) 2024-02-22
US12459973B2 (en) 2025-11-04
CN114641486A (zh) 2022-06-17
CN114641486B (zh) 2025-04-01
AU2020360716B2 (en) 2025-09-04
EP4041748B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL286462A (en) Protein tyrosine phosphatase inhibitors
IL289534A (en) Parp1 inhibitors
IL280290A (en) Il2 agonists
IL282179A (en) Protein tyrosine phosphatase inhibitors
EP3843714C0 (en) CD73 INHIBITORS
EP4007752C0 (en) Kif18a inhibitors
EP4007753C0 (en) Kif18a inhibitors
EP4007756C0 (en) KIF18A INHIBITORS
EP3652329A4 (en) COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN
MA52413A (fr) Inhibiteurs de cd73
HUE057323T2 (hu) Hemoglobin módosítására alkalmas 2-formil-3-hidroxi-feniloximetil-vegyületek
DK4051688T3 (da) Cd73-hæmmere
EP3423451A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
MA49908A (fr) Composés inhibant la protéine mcl-1
EP3787635A4 (en) CD73 INHIBITORS
IL304110A (en) Keap1–nrf2 protein–protein interaction inhibitors
EP3999517A4 (en) CD73 INHIBITORS
EP3679031A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
EP3980011C0 (en) SARM1 HIBITORS
IL290878A (en) Protein based cannabis compositions
EP3884940A4 (en) Novel imidazole derivative
EP3761962A4 (en) EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS
IL280047A (en) Formulation of cannabinoid compounds
EP4257597A4 (en) LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
IL285546A (en) Compounds and methods for reducing kcnt1 expression